Researcher
Frederik Cleeren
- Disciplines:Other chemical sciences, Chemical product design and formulation, Biomaterials engineering, Medical imaging and therapy, Medicinal products
Affiliations
- Radiopharmaceutical Research (Division)
Member
From24 Sep 2012 → Today
Projects
1 - 10 of 18
- Generator based therapeutic radiopharmaceutical production for targeting of fibroblast activation protein (FAP)From1 Oct 2023 → TodayFunding: FWO senior postdoctoral fellowship
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals for pancreatic cancerFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Research on radioactive nuclei at ISOLDE-CERN, SPIRAL2- GANIL and MEDICIS-CERNFrom1 Jan 2023 → TodayFunding: FWO International research infrastructure (IRI)
- A fully automated system for the generation of stained tissue slices for scientific research.From1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- IMAGINATION : IMAGing bIomarkers for diagNosis, therAnosTIcs and drug develOpmeNtFrom1 Oct 2022 → TodayFunding: IOF - mandates
- 161Tb-labeled radiopharmaceuticals targeting mucin receptors for treatment of pancreatic cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Targeted alpha therapy of pancreatic tumors in a theranostic settingFrom1 Oct 2022 → TodayFunding: BOF - projects, Fund Recuperation Fiscal Exemption
- Development and preclinical evaluation of innovative NANOBODY® based radioprobes for imaging and targeted radionuclide therapy.From12 Aug 2021 → TodayFunding: Baekeland
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals targeting CXCR4From10 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Preclinical evaluation of novel radionuclide therapies in different cancer modelsFrom8 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 39
- Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics(2023)
Authors: Stephen Ahenkorah, Frederik Cleeren
- Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist(2023)
Authors: Stephen Ahenkorah, Christopher Cawthorne, Christophe Deroose, Thomas Cardinaels, Guy Bormans, Frederik Cleeren
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board(2023)
Authors: Frederik Cleeren
- Development of theranostic somatostatin analogues for the treatment of neuroendocrine tumors(2022)
Authors: Frederik Cleeren, Thomas Cardinaels
- 3p-C-NETA: A versatile and effective chelator for
development of Al18F-labeled and therapeutic
radiopharmaceuticals(2022)
Authors: Stephen Ahenkorah, Christopher Cawthorne, Christophe Deroose, Thomas Cardinaels, Willy Gsell, Guy Bormans, Frederik Cleeren
Pages: 5971 - 5985 - Design and development of a new vector platform for CXCR4-targeted molecular imaging and radionuclide therapy(2022)
Authors: Kaat Luyten, Guy Bormans, Frederik Cleeren
- D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy(2021)
Authors: Kaat Luyten, Tom Van Loy, Christopher Cawthorne, Christophe Deroose, Dominique Schols, Guy Bormans, Frederik Cleeren
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board(2021)
Authors: Frederik Cleeren
- Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability(2021)
Authors: Irwin Cassells, Stephen Ahenkorah, Thomas Cardinaels, Guy Bormans, Frederik Cleeren
- Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside(2021)
Authors: Stephen Ahenkorah, Irwin Cassells, Christophe Deroose, Thomas Cardinaels, Guy Bormans, Frederik Cleeren